Publication details

Pacient s fenylketonurií: současné léčebné možnosti a výhled do budoucnosti

Title in English Patient with phenylketonuria: current treatment options and future prospects
Authors

PROCHÁZKOVÁ Dagmar KONEČNÁ Petra SLABÁ Kateřina

Year of publication 2020
Type Article in Periodical
Magazine / Source Pediatrie pro praxi
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.solen.cz/artkey/ped-202005-0007_pacient_s_fenylketonurii_soucasne_lecebne_moznosti_a_vyhled_do_budoucnosti.php?back=%2Fsearch.php%3Fquery%3Dpo%2525B9kozen%2525ED%252520m%2525EDchy%26sfrom%3D990%26spage%3D30
Doi http://dx.doi.org/10.36290/ped.2020.069
Keywords Inborn errors of metabolism; phenylketonuria; treatment.
Description Phenylketonuria (PKU) is an autosomal recessive inherited disorder of the metabolism of the amino acid phenylalanine, which is caused by a deficiency of the enzyme phenylalanine hydroxylase in the liver. Untreated PKU primarily leads to cognitive impairment. The most commonly used treatment is a low-protein diet with a low content of phenylalanine in the diet (phenylalanine free amino acid mixtures, glycomacropeptide-GMP, neutral long-chain amino acids-LNNAs). Decreased organoleptic properties of a low-protein diet lead to poor adherence to a diet with possible cognitive and executive dysfunction. For this reasons, new treatment options are sought, ei. treatment with cofactor BH4, enzyme replacement therapy, the use of probiotics and potentially gene therapy. The Key European Guidelines for the diagnosis and manamegent of patients with phenylketonuria (PKU) were developed to optimise PKU care.

You are running an old browser version. We recommend updating your browser to its latest version.

More info